Recent asthma treatment guidelines strongly endorse a specific combination of inhaled corticosteroids and bronchodilators, raising concerns about potential conflicts of interest. With a significant portion of the guidelines' authors receiving payments from the drug's manufacturer, questions arise regarding the integrity of the research supporting this recommendation. The reliance on studies funded by the pharmaceutical industry highlights the need for independent research to explore alternative treatment options.
